Company intelligence / Profile preview

EGE

Pleasanton, California, United States

Ownership: Private
Development stage: Other

Overview

EGE Bio is a biotechnology company dedicated to revolutionizing the treatment of autoimmune diseases through precision medicine. Founded in 2024 and based in Pleasanton, California, the company utilizes a combination of epigenetic gene editing, CRISPR, and RNA interference (RNAi) technologies to address the underlying genetic causes of immune system deficiencies. EGE focuses on developing curative therapies that offer long-term solutions rather than temporary symptom relief. Through strategic partnerships, such as with Turquoise Biotechnologies for exosome-based delivery, EGE aims to ensure highly targeted and effective drug administration.

Therapeutic areas: Immunology
Modalities: CRISPR-based therapyRNA therapyEpigenetic gene editingSmall interfering RNA
Industry: Biotech

Partnerships

Turquoise Biotechnologies

Beyond the preview

Go deeper on EGE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EGE.

Explore the full profile